Victor Rossetto Barboza , Gabriel Taricani Kubota , Valquíria Aparecida da Silva , Luciana Mendonça Barbosa , Debora Arnaut , Antônia Lilian de Lima Rodrigues , Ricardo Galhardoni , Egberto Reis Barbosa , Andre Russowsky Brunoni , Manoel Jacobsen Teixeira , Rubens Gisbert Cury , Daniel Ciampi de Andrade
{"title":"后脑岛重复经颅磁刺激治疗帕金森病患者的慢性疼痛--疼痛类型很重要:双盲随机假对照试验","authors":"Victor Rossetto Barboza , Gabriel Taricani Kubota , Valquíria Aparecida da Silva , Luciana Mendonça Barbosa , Debora Arnaut , Antônia Lilian de Lima Rodrigues , Ricardo Galhardoni , Egberto Reis Barbosa , Andre Russowsky Brunoni , Manoel Jacobsen Teixeira , Rubens Gisbert Cury , Daniel Ciampi de Andrade","doi":"10.1016/j.neucli.2024.102994","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Altered somatosensory processing in the posterior insula may play a role in chronic pain development and contribute to Parkinson disease (PD)-related pain. Posterior-superior insula (PSI) repetitive transcranial magnetic stimulation (rTMS) has been demonstrated to have analgesic effects among patients with some chronic pain conditions. This study aimed at assessing the efficacy of PSI-rTMS for treating PD-related pain.</p></div><div><h3>Methods</h3><p>This was a double-blinded, randomized, sham-controlled, parallel-arm trial (NCT03504748). People with PD (PwP)-related chronic pain underwent five daily PSI-rTMS sessions for a week, followed by once weekly maintenance stimulations for seven weeks. rTMS was delivered at 10 Hz and 80% of the resting motor threshold. The primary outcome was <em>a</em> ≥ 30% pain intensity reduction at 8 weeks compared to baseline. Functionality, mood, cognitive, motor status, and somatosensory thresholds were also assessed.</p></div><div><h3>Results</h3><p>Twenty-five patients were enrolled. Mean age was 55.2 ± 9.5 years-old, and 56% were female. Nociceptive pain accounted for 60%, and neuropathic and nociplastic for 20% each. No significant difference was found for 30% pain reduction response rates between active (42.7%) and sham groups (14.6%, <em>p</em> = 0.26). Secondary clinical outcomes and sensory thresholds also did not differ significantly. In a <em>post hoc</em> analysis, PwP with nociceptive pain sub-type experienced more pain relief after active (85.7%) compared to sham PSI-rTMS (25%, <em>p</em> = 0.032).</p></div><div><h3>Conclusion</h3><p>Our preliminary results suggest that different types of PD-related pain may respond differently to treatment, and therefore people with PD may benefit from having PD-related pain well characterized in research trials and in clinical practice.</p></div>","PeriodicalId":19134,"journal":{"name":"Neurophysiologie Clinique/Clinical Neurophysiology","volume":"54 5","pages":"Article 102994"},"PeriodicalIF":2.7000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0987705324000522/pdfft?md5=b333cbe05876b0562fd69818141dbb1d&pid=1-s2.0-S0987705324000522-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Posterior insula repetitive transcranial magnetic stimulation for chronic pain in patients with Parkinson disease – pain type matters: A double-blinded randomized sham-controlled trial\",\"authors\":\"Victor Rossetto Barboza , Gabriel Taricani Kubota , Valquíria Aparecida da Silva , Luciana Mendonça Barbosa , Debora Arnaut , Antônia Lilian de Lima Rodrigues , Ricardo Galhardoni , Egberto Reis Barbosa , Andre Russowsky Brunoni , Manoel Jacobsen Teixeira , Rubens Gisbert Cury , Daniel Ciampi de Andrade\",\"doi\":\"10.1016/j.neucli.2024.102994\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Altered somatosensory processing in the posterior insula may play a role in chronic pain development and contribute to Parkinson disease (PD)-related pain. Posterior-superior insula (PSI) repetitive transcranial magnetic stimulation (rTMS) has been demonstrated to have analgesic effects among patients with some chronic pain conditions. This study aimed at assessing the efficacy of PSI-rTMS for treating PD-related pain.</p></div><div><h3>Methods</h3><p>This was a double-blinded, randomized, sham-controlled, parallel-arm trial (NCT03504748). People with PD (PwP)-related chronic pain underwent five daily PSI-rTMS sessions for a week, followed by once weekly maintenance stimulations for seven weeks. rTMS was delivered at 10 Hz and 80% of the resting motor threshold. The primary outcome was <em>a</em> ≥ 30% pain intensity reduction at 8 weeks compared to baseline. Functionality, mood, cognitive, motor status, and somatosensory thresholds were also assessed.</p></div><div><h3>Results</h3><p>Twenty-five patients were enrolled. Mean age was 55.2 ± 9.5 years-old, and 56% were female. Nociceptive pain accounted for 60%, and neuropathic and nociplastic for 20% each. No significant difference was found for 30% pain reduction response rates between active (42.7%) and sham groups (14.6%, <em>p</em> = 0.26). Secondary clinical outcomes and sensory thresholds also did not differ significantly. In a <em>post hoc</em> analysis, PwP with nociceptive pain sub-type experienced more pain relief after active (85.7%) compared to sham PSI-rTMS (25%, <em>p</em> = 0.032).</p></div><div><h3>Conclusion</h3><p>Our preliminary results suggest that different types of PD-related pain may respond differently to treatment, and therefore people with PD may benefit from having PD-related pain well characterized in research trials and in clinical practice.</p></div>\",\"PeriodicalId\":19134,\"journal\":{\"name\":\"Neurophysiologie Clinique/Clinical Neurophysiology\",\"volume\":\"54 5\",\"pages\":\"Article 102994\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0987705324000522/pdfft?md5=b333cbe05876b0562fd69818141dbb1d&pid=1-s2.0-S0987705324000522-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurophysiologie Clinique/Clinical Neurophysiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0987705324000522\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurophysiologie Clinique/Clinical Neurophysiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0987705324000522","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Posterior insula repetitive transcranial magnetic stimulation for chronic pain in patients with Parkinson disease – pain type matters: A double-blinded randomized sham-controlled trial
Objectives
Altered somatosensory processing in the posterior insula may play a role in chronic pain development and contribute to Parkinson disease (PD)-related pain. Posterior-superior insula (PSI) repetitive transcranial magnetic stimulation (rTMS) has been demonstrated to have analgesic effects among patients with some chronic pain conditions. This study aimed at assessing the efficacy of PSI-rTMS for treating PD-related pain.
Methods
This was a double-blinded, randomized, sham-controlled, parallel-arm trial (NCT03504748). People with PD (PwP)-related chronic pain underwent five daily PSI-rTMS sessions for a week, followed by once weekly maintenance stimulations for seven weeks. rTMS was delivered at 10 Hz and 80% of the resting motor threshold. The primary outcome was a ≥ 30% pain intensity reduction at 8 weeks compared to baseline. Functionality, mood, cognitive, motor status, and somatosensory thresholds were also assessed.
Results
Twenty-five patients were enrolled. Mean age was 55.2 ± 9.5 years-old, and 56% were female. Nociceptive pain accounted for 60%, and neuropathic and nociplastic for 20% each. No significant difference was found for 30% pain reduction response rates between active (42.7%) and sham groups (14.6%, p = 0.26). Secondary clinical outcomes and sensory thresholds also did not differ significantly. In a post hoc analysis, PwP with nociceptive pain sub-type experienced more pain relief after active (85.7%) compared to sham PSI-rTMS (25%, p = 0.032).
Conclusion
Our preliminary results suggest that different types of PD-related pain may respond differently to treatment, and therefore people with PD may benefit from having PD-related pain well characterized in research trials and in clinical practice.
期刊介绍:
Neurophysiologie Clinique / Clinical Neurophysiology (NCCN) is the official organ of the French Society of Clinical Neurophysiology (SNCLF). This journal is published 6 times a year, and is aimed at an international readership, with articles written in English. These can take the form of original research papers, comprehensive review articles, viewpoints, short communications, technical notes, editorials or letters to the Editor. The theme is the neurophysiological investigation of central or peripheral nervous system or muscle in healthy humans or patients. The journal focuses on key areas of clinical neurophysiology: electro- or magneto-encephalography, evoked potentials of all modalities, electroneuromyography, sleep, pain, posture, balance, motor control, autonomic nervous system, cognition, invasive and non-invasive neuromodulation, signal processing, bio-engineering, functional imaging.